As head of Seattle Genetics since 2002, Clay Siegall is proud that the company was the first to receive FDA approval for an antibody-drug conjugate (ADC), which is marketed under the brand name ADCETRIS. Used to treat Hodgkin Lymphoma patients who have not responded to chemotherapy, ADCETRIS’s antibody targets lymphoma cells and then delivers an anticancer drug. Siegall has said that Seattle Genetics is working to gain FDA approval to widen ADCETRIS’s use, which combined with the company’s plans to augment its drug pipeline, interests investors. Under Siegall’s leadership, Seattle Genetics’ stock price has nearly tripled in the last five years.
A frequent featured speaker at industry events, Siegall impresses audiences with his dedication to improving therapies for cancer patients. One of his responsibilities as CEO is to raise capital for Seattle Genetics to continue their research, an area that Siegall excels in. Bringing in more than $350 million from licensing agreements alone, Siegall ensures that Seattle Genetics will continue to develop breakthrough therapies that will benefit cancer patients.
With a dozen new drugs in development, Siegall is focusing on increasing the therapies available for cancer patients, which has been his goal since he co-founded Seattle Genetics in 1998. Xconomy reports that Siegall, in addition to running an ambitious biotechnology company, is on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance and on the Board of Directors of the Washington Biotechnology and Biomedical Association. Also serving on the Boards of Directors for three private biotechnology companies, Siegall is extremely busy; nevertheless, he told Seeking Alpha “We think we can be the next big important biotech company.” This means Seattle Genetics would need to develop drug after drug, however, when it comes to new ways to meet cancer patients unmet needs, Siegall does not rest.